Study guide

9.3 Acute Pain Management in Patients on Maintenance MOUD (Methadone, Buprenorphine, Naltrexone)

Certified Addictions Registered Nurse - Advanced Practice CARN-AP

Track your progress as you read

Finished sections get a check mark.

1 Introduction: The CARN-AP Examination & Foundations of Advanced Addictions Practice

About the CARN-AP Examination: Blueprint, Scoring & Eligibility The Neurobiology of Addiction: Binge, Withdrawal & Preoccupation Screening, SBIRT & the ASAM Criteria Levels of Care

2 Chapter 1: Opioid Use Disorder: Assessment, Overdose Response & Methadone Maintenance

1.1 OUD Assessment, DSM-5-TR Diagnostic Criteria, and Clinical Opiate Withdrawal Scale (COWS) 1.2 Methadone Pharmacology, OTP Federal Regulations, QTc Prolongation & CYP450 Interactions 1.3 Opioid Overdose Assessment, Harm Reduction, Naloxone Formulations & Nalmefene

3 Chapter 2: Buprenorphine Protocols, Long-Acting Injectables & Naltrexone

2.1 Buprenorphine Pharmacology, Standard Office/Home Induction & Precipitated Withdrawal Management 2.2 Low-Dose Micro-Induction (Bernese Method) & Fentanyl Transition Strategies 2.3 Long-Acting Injectable Buprenorphine (Sublocade, Brixadi) & Extended-Release Naltrexone (Vivitrol)

4 Chapter 3: Alcohol Use Disorder: Neurobiology, Assessment & Acute Withdrawal

3.1 AUD Neurobiology, Epidemiology, Screening Instruments (AUDIT, AUDIT-C, CAGE) & Laboratory Biomarkers 3.2 Alcohol Withdrawal Syndrome, CIWA-Ar Protocol, Symptom-Triggered Benzodiazepine Regimens & Delirium Tremens 3.3 Wernicke-Korsakoff Syndrome, High-Dose Parenteral Thiamine Protocols & Acute Medical Complications

5 Chapter 4: Medications for Alcohol Use Disorder (MAUD)

4.1 Oral and Injectable Naltrexone for AUD: Mechanism, Prescribing Protocols & Clinical Efficacy 4.2 Acamprosate Calcium: NMDA Modulation, Renal Dosing Parameters & Abstinence Maintenance 4.3 Disulfiram and Second-Line / Off-Label MAUDs: Topiramate, Gabapentin & Baclofen

6 Chapter 5: Stimulant, Sedative-Hypnotic & Synthetic Substance Use Disorders

5.1 Stimulant Use Disorder (Cocaine & Methamphetamine): Neurotoxicity, Medical Emergencies & Evidence-Based Interventions 5.2 Sedative, Hypnotic, and Anxiolytic Disorders: Dependence Physiology, Risks & Outpatient Tapering Protocols 5.3 Emerging Synthetic Drugs: Fentanyl Analogues, Synthetic Cathinones, Cannabinoids & Xylazine-Associated Necrotic Wounds

7 Chapter 6: Tobacco and Cannabis Use Disorders: Evidence-Based Pharmacotherapy & Interventions

6.1 Tobacco Use Disorder & Nicotine Dependence: Dual NRT, Varenicline & Bupropion Prescribing Protocols 6.2 Cannabis Use Disorder, Synthetic Cannabinoids & Cannabinoid Hyperemesis Syndrome 6.3 Behavioral Therapies in Substance Use: Motivational Interviewing, CBT & Contingency Management

8 Chapter 7: Psychiatric Differential Diagnosis & Medical Mimics in Addictions

7.1 Diagnostic Formulation: Primary vs. Substance-Induced Psychiatric Disorders & The 30-Day Rule 7.2 Endocrine, Neurological, and Metabolic Mimics of Substance Intoxication and Withdrawal 7.3 Decisional Capacity, Competency, and Involuntary Commitment in Acute Addiction Practice

9 Chapter 8: Co-Occurring Psychiatric Disorders: Integrated Treatment Planning

8.1 Integrated Dual Diagnosis Treatment (IDDT) Framework & High-Prevalence Mood / Anxiety Co-Occurring Disorders 8.2 Complex Severe Mental Illness: Psychotic Disorders, Bipolar Disorder & Borderline Personality in Addictions 8.3 Trauma-Informed Care, PTSD, and Addictions: Evidence-Based Integrated Psychotherapy

10 Chapter 9: Pain Management in Substance Use Disorders & CDC 2022 Guidelines

9.1 CDC 2022 Clinical Practice Guideline for Prescribing Opioids for Chronic Pain: Individualized Assessment vs. Hard Caps 9.2 Multimodal Non-Opioid Pharmacotherapy, Interventional Modalities & Non-Pharmacological Strategies 9.3 Acute Pain Management in Patients on Maintenance MOUD (Methadone, Buprenorphine, Naltrexone)

11 Chapter 10: Perinatal Substance Use, Neonatal Abstinence & Infectious Complications

10.1 Perinatal Substance Use Disorder: ACOG/ASAM Guidelines, MOTHER Trial & Maintenance MOUD 10.2 Neonatal Abstinence Syndrome (NAS/NOWS): Finnegan Scoring vs. Eat, Sleep, Console (ESC) & Breastfeeding 10.3 Infectious Complications in People Who Inject Drugs: Viral Hepatitis, HIV, Endocarditis & PrEP/PEP

12 Chapter 11: Federal Regulations, Confidentiality & Controlled Substance Prescribing

11.1 Controlled Substances Act, DEA Registration, Schedule Classifications & MAT Act of 2023 11.2 Confidentiality of Substance Use Disorder Patient Records: 42 CFR Part 2 (2024 Final Rule) & HIPAA Harmonization 11.3 Prescription Drug Monitoring Programs (PDMP) & Urine Drug Testing (UDT) Interpretation

13 Chapter 12: APRN Scope of Practice, Ethical Foundations, Harm Reduction & Research Literacy

12.1 APRN Scope of Practice, Prescriptive Authority & Collaborative Practice Regulations 12.2 Ethical Dilemmas in Addictions Nursing: Stigma, Autonomy, Justice, and Maternal/Fetal Rights 12.3 Harm Reduction Philosophy, Syringe Service Programs, Drug Checking & Overdose Prevention 12.4 Landmark Clinical Trials & Research Literacy in Addictions Medicine

14 Chapter 13: Stimulant Use Disorder in Depth — Methamphetamine, Withdrawal, Treatment & Harm Reduction

13.1 Methamphetamine Use Disorder: Pharmacology, Medical & Psychiatric Sequelae 13.2 Stimulant Withdrawal, Craving & Contingency Management 13.3 Pharmacotherapy Research for Stimulant Use Disorder 13.4 Stimulant Harm Reduction, Overamping & Patient Education

15 Chapter 14: Medical Consequences of Alcohol Use — Liver, Heart, Cancer & Nutrition

14.1 Alcohol-Associated Liver Disease: Staging, Scoring & Management 14.2 Cardiovascular, Oncologic & Nutritional Consequences of Alcohol

16 Chapter 15: Brief Intervention, Drinking Goals & Recovery Support in Alcohol Use Disorder

15.1 Brief Intervention, Drinking Goals & Shared Decision Making in AUD 15.2 Relapse Prevention, Mutual-Help Programs & Recovery Support

17 Chapter 16: Tobacco Use Disorder in Depth — Neurobiology, Assessment & Special Populations

16.1 Nicotine Neurobiology, Epidemiology & the Tobacco Product Landscape 16.2 Tobacco Assessment & Behavioral Treatment: 5 A's, Quitlines & Incentives 16.3 Tobacco Treatment in Special Populations & Co-Occurring Disorders

18 Chapter 17: Cannabis Use Disorder in Depth — Products, Treatment & Policy

17.1 Cannabinoid Pharmacology, Potency & the Modern Product Landscape 17.2 Cannabis Use Disorder: Epidemiology, Assessment & Treatment Evidence 17.3 Medical Cannabis, Legalization Policy, Adolescent Risk & Patient Education

19 Chapter 18: Other Use Disorders — Inhalants, Hallucinogens, Process Addictions & Prescription/OTC Misuse

18.1 Inhalant Use Disorder: Volatile Solvents, Nitrous Oxide & Alkyl Nitrites 18.2 Hallucinogens & Dissociatives: Classic Psychedelics, PCP, Ketamine & HPPD 18.3 Process (Behavioral) Addictions: Gambling Disorder, Gaming & Compulsive Behaviors 18.4 Prescription & Over-the-Counter Substance Misuse: Opioids, Stimulants, Kratom & DXM

20 Chapter 19: Educating Patients, Families & the Public (CARN-AP Activity Area III)

19.1 Designing Health Teaching: Literacy, Readiness, Culture & Teach-Back 19.2 Medication Education, Informed Consent & Informed Refusal 19.3 Family & Support-System Education: CRAFT, Al-Anon & Overdose Prevention Teaching 19.4 Public, Professional & Anticipatory Guidance: Prevention and Advocacy Teaching

21 Chapter 20: Consultation, Collaboration & Care Coordination (CARN-AP Activity Area IV)

20.1 The APRN Consultation Process & Communicating Recommendations 20.2 Interprofessional Collaboration, Care Coordination & Transitions of Care 20.3 Community Resources, Systems Navigation & Collaborative Documentation

22 Chapter 21: Quality Improvement, Evidence & Leadership in Addictions Nursing (CARN-AP Activity Area V)

21.1 Outcome Measurement & Continuous Quality Improvement in Addictions Care 21.2 Policy Advocacy, Leadership & the Determinants of Addiction

9.3 Acute Pain Management in Patients on Maintenance MOUD (Methadone, Buprenorphine, Naltrexone)

Key Takeaways Explain This Topic AI

Maintenance MOUD (methadone or buprenorphine) does NOT provide adequate analgesia for acute severe pain due to receptor tolerance and a brief 4–8 hour duration of antinociceptive efficacy compared to 24–36 hour withdrawal suppression.

Opioid-tolerant patients maintained on MOUD require significantly HIGHER doses of full-agonist opioids administered at SHORTER dosing intervals for acute breakthrough pain.

Withholding or discontinuing baseline MOUD during acute trauma, illness, or surgery is strictly contraindicated and precipitates severe acute withdrawal, uncontrolled pain, and hemodynamic instability.

The historical practice of stopping buprenorphine prior to surgery is retired; current ASAM/ASA guidelines recommend continuing buprenorphine and adding high-affinity full agonists or dividing buprenorphine doses.

Active naltrexone maintenance competitively blocks all opioid analgesia; emergency surgical pain requires aggressive multimodal non-opioid and regional anesthesia, or high-potency opioids in an ICU/monitored setting equipped for immediate mechanical ventilation.

Last updated: September 2026

9.3 Acute Pain Management in Patients on Maintenance MOUD (Methadone, Buprenorphine, Naltrexone)

Core Clinical Competency: The Advanced Practice Registered Nurse (APRN) must manage acute traumatic and postoperative pain in patients maintained on Medications for Opioid Use Disorder (MOUD). The APRN must apply precise neuropharmacological principles, debunk clinical myths regarding pain tolerance, navigate competitive opioid receptor dynamics, and prevent both undertreated agony and iatrogenic withdrawal.

1. Cardinal Clinical Principles of Acute Pain in MOUD Patients

Managing acute traumatic, surgical, or medical pain in patients receiving MOUD requires advanced understanding of neuroadaptation, opioid cross-tolerance, and receptor kinetics. Three cardinal principles guide evidence-based care: Three Cardinal Principles of Acute Pain Management in MOUD:

  • ┌─────────────────────────────────────────────────────────────────────────┐
  • │ Principle 1: MOUD Does NOT Provide Analgesia for Severe Acute Pain │
  • │ • Chronic maintenance satisfies physical dependence and suppresses │
  • │ cravings, but analgesic duration is only 4 to 8 hours. │
  • └────────────────────────────────────┬────────────────────────────────────┘
  • ▼
  • ┌─────────────────────────────────────────────────────────────────────────┐
  • │ Principle 2: Opioid Tolerance Mandates Higher Doses at Shorter Intervals│
  • │ • Downregulated mu receptors and cross-tolerance require 1.5x to 3x │
  • │ higher doses of full agonists administered every 2 to 3 hours. │
  • └────────────────────────────────────┬────────────────────────────────────┘
  • ▼
  • ┌─────────────────────────────────────────────────────────────────────────┐
  • │ Principle 3: NEVER Withhold or Abruptly Discontinue Baseline MOUD │
  • │ • Discontinuation triggers catastrophic withdrawal, hyperalgesia, │
  • │ autonomic instability, and heightened risk of illicit relapse. │
  • └─────────────────────────────────────────────────────────────────────────┘
  • Clinical Myth vs. Neurobiological Reality
  • Myth 1: "The patient's daily methadone or buprenorphine dose covers their acute pain."

Reality: While the terminal half-life of methadone (15–60 hours) and buprenorphine (24–42 hours) suppresses withdrawal and cravings for 24 to 36+ hours, the duration of active analgesia is only 4 to 8 hours . Patients on stable once-daily MOUD experience zero baseline analgesic protection against new acute tissue trauma.

Myth 2: "Providing full agonist opioids to an MOUD patient will trigger an immediate addiction relapse."

Reality: Undertreating severe acute pain creates a massive hyperadrenergic surge, severe suffering, and intense craving, drastically increasing the risk of illicit drug acquisition. Relieving acute pain compassionately and adequately with scheduled analgesics stabilizes the patient and protects recovery.

Myth 3: "High opioid requests represent drug-seeking behavior or pseudoaddiction."

Reality: Chronic opioid exposure causes profound neurobiological desensitization and downregulation of central mu-opioid receptors. These patients exhibit genuine pharmacological cross-tolerance and require substantially higher doses of full agonists to achieve equivalent antinociception. Behaviors driven by undertreated agony represent pseudoaddiction , which resolves promptly when adequate analgesia is delivered.

2. Clinical Protocol: Acute Pain Management in Methadone Maintenance

Patients enrolled in Opioid Treatment Programs (OTPs) receiving daily methadone maintenance require careful coordination across inpatient and outpatient care. Acute Pain Protocol in Methadone Maintenance:

  • [Patient on Methadone Maintenance Admitted for Acute Pain / Surgery]
  • │
  • ▼
  • [1. Verification of Baseline Dose]
  • Contact OTP directly or verify via PDMP / secure hospital records
  • Document exact dose, date/time of last dose, and OTP contact details
  • │
  • ▼
  • [2. Maintenance Dose Continuation]
  • CONTINUE full verified methadone dose throughout hospitalization
  • Administer as scheduled (federal regulations explicitly allow inpatient
  • methadone maintenance for acute medical/surgical conditions)
  • │
  • ▼
  • [3. Acute Breakthrough Analgesia]
  • Multi-modal baseline: IV acetaminophen + IV ketorolac (if not contraindicated)
  • Add scheduled or PRN short-acting full agonist (IV hydromorphone, IV morphine,
  • or oral oxycodone)
  • Dosing: 1.5x to 3x higher than opioid-naive doses; shorten dosing interval
  • (e.g., q2-3h instead of q4-6h)
  • │
  • ▼
  • [4. Alternative / Adjunctive Strategy: Methadone Dose-Splitting]
  • In consultation with pain service, divide daily baseline methadone into
  • equal TID or QID doses (e.g., 30 mg q8h instead of 90 mg once daily)
  • Harnesses methadone's 6- to 8-hour analgesic duration for continuous baseline relief
  • Clinical Steps & Federal Regulations

OTP Verification: Immediately contact the patient's OTP to confirm the exact daily dose and time of the last dose. Federal law (Title 21, Code of Federal Regulations, Part 1306.07[c]) explicitly allows acute care hospitals to administer methadone to maintain maintenance therapy during medical or surgical admissions.

Continue Verified Baseline Dose: Never hold or reduce the baseline dose. If the patient is NPO, administer the baseline dose parenterally (intravenous or subcutaneous methadone conversion: 50% of oral dose , divided into two to three daily doses due to higher parenteral bioavailability).

Breakthrough Analgesia with Short-Acting Full Agonists: Prescribe scheduled or PRN immediate-release full mu agonists (hydromorphone, fentanyl, oxycodone, morphine). Titrate aggressively to clinical comfort. Opioid-tolerant patients require doses 50% to 200% higher than standard opioid-naive parameters, with narrowed intervals (every 2 to 3 hours).

Methadone Dose-Splitting Strategy: Because methadone provides analgesia for only 6 to 8 hours, dividing the patient's verified total daily dose into three or four divided doses (e.g., every 6 or 8 hours) harnesses methadone's intrinsic antinociceptive properties, establishing continuous baseline relief.

3. Clinical Protocol: Acute Pain Management in Buprenorphine Maintenance Buprenorphine Acute Pain Paradigm Shift:

[HISTORICAL PRACTICE - RETIRED / HARMFUL]:

Discontinue buprenorphine 48-72 hours pre-op ──> Patient enters acute withdrawal,

severe pain, hemodynamic instability, delayed recovery, and high relapse risk!

[MODERN EVIDENCE-BASED PRACTICE - ASAM / ASA GUIDELINES]:

CONTINUE Buprenorphine Maintenance Throughout the Perioperative Period!

  • │
  • ┌──────────────────┼──────────────────┐
  • ▼ ▼ ▼
  • [Pathway A] [Pathway B] [Pathway C]
  • Continue Baseline Split Baseline Dose Escalation
  • Buprenorphine & Buprenorphine into Buprenorphine PRN
  • Add Full Agonists Divided Doses (Add 2-4 mg SL q4-6h
  • (Titrate IV Fentanyl (e.g., 8 mg TID up to 24-32 mg/day)
  • or Hydromorphone) or 4 mg QID) Ideal for mild/mod
  • Ideal for severe Ideal for moderate acute surgical pain
  • major surgical pain inpatient pain
  • Retirement of the Historical Practice

Historically, surgeons and anesthesiologists instructed patients to stop buprenorphine 3 to 5 days prior to surgery, fearing that its high mu-receptor affinity ( K i ≈ 0.219 nM K_i \approx 0.219\text{ nM} K i ​ ≈ 0.219 nM ) would prevent full agonist opioids from binding. This practice is now completely retired . Abrupt discontinuation precipitates acute withdrawal, heightens surgical stress, induces neuroendocrine instability, and leaves the patient vulnerable to severe postoperative pain that is difficult to manage.

Modern ASAM and ASA Endorsed Pathways

Pathway A (Continue Baseline Buprenorphine and Add High-Affinity Full Agonists):

Continue the patient's baseline buprenorphine dose (e.g., 16 mg daily).

At 16 mg/day, buprenorphine occupies approximately 80% to 85% of mu-opioid receptors , leaving 15% to 20% unoccupied .

Administer high-potency, high-affinity full mu agonists ( intravenous fentanyl or hydromorphone ) titrated to effect. These agents bind to remaining unoccupied receptors and, at higher concentrations, compete with and overcome buprenorphine binding to provide robust acute antinociception.

Advantage: Zero withdrawal risk; rapid transition back to standard maintenance upon discharge without re-induction.

Pathway B (Split Baseline Buprenorphine into Divided Doses):

Divide the patient's daily maintenance dose into TID or QID dosing (e.g., a patient on 24 mg daily receives 8 mg SL every 8 hours; a patient on 16 mg daily receives 4 mg SL every 6 hours).

Buprenorphine is a potent analgesic, but its analgesic effect lasts only 6 to 8 hours. Dividing the daily dose provides steady, 24-hour baseline analgesia.

Pathway C (Supplemental Buprenorphine Dosing):

In patients experiencing mild-to-moderate acute pain, add supplemental buprenorphine (e.g., 2 mg to 4 mg SL every 4 to 6 hours PRN) up to a maximum daily ceiling of 24 mg to 32 mg/day .

4. Clinical Protocol: Acute Pain Management in Naltrexone Maintenance

Naltrexone is a pure, insurmountable competitive mu-opioid receptor antagonist with an extraordinarily high binding affinity. It renders standard doses of full-agonist opioids completely clinically ineffective. Naltrexone Perioperative & Emergency Management Algorithm:

  • [Patient on Naltrexone Maintenance]
  • │
  • ┌────────────────────┴────────────────────┐
  • ▼ ▼
  • [Elective / Scheduled Surgery] [Emergency Surgery / Acute Trauma]

• Oral Naltrexone: • Naltrexone is ACTIVELY BLOCKING!

Discontinue ≥72 hours pre-op • Standard opioids will FAIL!

  • Extended-Release IM (Vivitrol): │
  • Schedule surgery at week 4 nadir ▼
  • (28-30 days post-injection) [Multi-Modal & Regional First-Line]
  • Neuraxial / Peripheral nerve blocks
  • IV Ketamine infusion (0.1-0.3 mg/kg/h)
  • IV Acetaminophen + IV Ketorolac
  • │
  • ▼
  • [If Opioids Clinically Mandatory]
  • High-potency opioids (Fentanyl)
  • Administer in ICU / Monitored PACU
  • Continuous Capnography & Telemetry
  • Mechanical ventilator on standby!
  • *Extreme risk of delayed apnea!*
  • Elective / Scheduled Procedures

Oral Naltrexone (ReVia): Must be discontinued at least 72 hours (3 days) prior to elective surgery to ensure complete receptor dissociation.

Injectable Extended-Release Naltrexone (Vivitrol 380 mg IM): Schedule elective surgery at the end of the 28-day dosing cycle (ideally weeks 4 to 5 post-injection ), when plasma concentrations have declined below therapeutic antagonist levels.

Emergency Surgery & Acute Severe Trauma (Active Naltrexone Blockade)

When a patient experiences severe acute trauma or requires emergency surgery while naltrexone is actively bound to mu-opioid receptors, the APRN and surgical team must execute a specialized protocol:

Aggressive Regional and Neuraxial Anesthesia: Maximize spinal anesthesia, epidural analgesia, and ultrasound-guided peripheral nerve blocks utilizing local anesthetics (e.g., bupivacaine, ropivacaine) which bypass opioid receptors entirely.

Systemic Non-Opioid Infusions: Initiate an intravenous ketamine infusion (0.1 mg to 0.3 mg/kg/hour) to provide potent N-methyl-D-aspartate (NMDA) receptor antagonism, alongside IV acetaminophen and IV NSAIDs (ketorolac).

Overcoming Competitive Blockade (High-Potency Opioids in Monitored ICU Setting):

If opioid analgesia is unavoidable, the clinician must administer high-affinity, high-potency synthetic opioids ( intravenous fentanyl or sufentanil ) at doses sufficient to competitively displace naltrexone from central mu receptors.

MANDATORY CRITICAL CARE SAFEGUARD: Overcoming competitive naltrexone blockade requires substantially higher opioid doses than normal. As the opioid overcomes the antagonist, or as naltrexone rapidly dissociates, the patient is at extreme risk for sudden, catastrophic, delayed respiratory depression and fatal apnea .

This therapy must only be conducted in an Intensive Care Unit (ICU), Post-Anesthesia Care Unit (PACU), or emergency resuscitation bay with continuous capnography (end-tidal CO2), continuous electrocardiographic telemetry, pulse oximetry, and immediate access to advanced airway equipment and mechanical ventilation .

5. Post-Discharge Planning, Care Coordination & MOUD Resumption Discharge Planning & MOUD Coordination Flowchart:

  • [Acute Surgical / Inpatient Phase Resolves]
  • │
  • ▼
  • [1. Taper & Discontinue Acute Full Agonists]
  • Taper short-acting opioids rapidly as tissue heals (3-5 day maximum outpatient supply)
  • Do NOT provide prolonged full agonist prescriptions to patients on MOUD
  • │
  • ▼
  • [2. Transition Back to Outpatient MOUD Provider]
  • Direct clinician-to-clinician sign-out with OTP (Methadone) or OBOT (Buprenorphine)
  • Confirm verified discharge medications, date of last dose, and next outpatient visit
  • │
  • ▼
  • [3. Specialized Protocol for Resuming Naltrexone]
  • Mandatory Opioid Washout: Must be entirely opioid-free for 7 to 10 days
  • (short-acting opioids) or 14 days (buprenorphine/methadone)
  • Verify negative UDT (including fentanyl/methadone)
  • Perform Naloxone Challenge Test (0.4 mg IV/SC) to confirm zero physical dependence
  • If challenge is negative, restart oral naltrexone 25-50 mg daily or administer IM Vivitrol
  • Methadone and Buprenorphine Discharge Continuity

Contact the outpatient OTP or buprenorphine provider prior to discharge. Provide formal documentation of all medications administered during hospitalization.

Discontinue inpatient short-acting breakthrough opioids prior to or at discharge. If severe post-discharge surgical pain persists, provide a strictly limited supply (e.g., 3 to 5 days maximum of short-acting full agonist) with close outpatient follow-up.

Resuming Naltrexone Maintenance

Patients whose naltrexone was stopped for surgery or who received full-agonist opioids require careful re-induction. Administering naltrexone prematurely precipitates severe, life-threatening withdrawal:

Drug-Free Clearance Interval: The patient must be completely abstinent from all short-acting opioids for a minimum of 7 to 10 days , and from long-acting opioids (methadone, buprenorphine) for at least 14 days .

Urine Toxicology: Obtain a definitive laboratory UDT confirming absence of opioids.

Naloxone Challenge Test: Administer an initial test dose of naloxone 0.4 mg IV or SC ; monitor for 30 to 60 minutes for objective signs of withdrawal (tachycardia, diaphoresis, piloerection). If no withdrawal occurs, it is safe to resume oral naltrexone (25 mg Day 1, then 50 mg daily) or administer extended-release intramuscular naltrexone (Vivitrol 380 mg IM).

6. MOUD Acute Pain Management Clinical Comparison Matrix

Clinical Domain Methadone Maintenance Buprenorphine Maintenance Naltrexone Maintenance

Baseline MOUD Handling CONTINUE baseline dose; verify with OTP. CONTINUE baseline dose (ASAM/ASA); split dosing optional. STOP 72h pre-op (oral) or schedule week 4 (Vivitrol).

Breakthrough Opioid Strategy Add short-acting full agonists at 1.5x–3x higher doses and shorter intervals (q2–3h). Add high-affinity full agonists (hydromorphone, fentanyl) titrated to overcome partial occupancy. AVOID opioids if possible. Standard doses fail completely. Overcoming blockade requires massive doses.

Non-Opioid Analgesic Role Standard multimodal adjuncts (acetaminophen, NSAIDs, topicals). Standard multimodal adjuncts (acetaminophen, NSAIDs, topicals). MANDATORY FIRST-LINE: Regional nerve blocks, ketamine infusion, IV NSAIDs/acetaminophen.

Major Acute Risks QTc prolongation with antiemetics; respiratory depression when adding full agonists. Historical error of stopping buprenorphine causing withdrawal; undertreated pain. Sudden catastrophic delayed respiratory depression if overcoming blockade; precipitated withdrawal on re-start.

Resumption / Discharge Rules Direct warm hand-off to OTP; eliminate breakthrough full agonists. Maintain regular buprenorphine; discontinue supplemental full agonists. Mandatory 7–10 day opioid-free washout + negative naloxone challenge before restarting.